Breast Cancer - Pipeline Review, H2 2013


#177828

521pages

Global Markets Direct

$ 2500

In Stock

 

Global Markets Directs, 'Breast Cancer Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. Breast Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Breast Cancer.
  • A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Breast Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Breast Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
Introduction 12
Breast Cancer Overview 13
Therapeutics Development 14
Breast Cancer Therapeutics under Development by Companies 16
Breast Cancer Therapeutics under Investigation by Universities/Institutes 37
Late Stage Products 44
Mid Clinical Stage Products 45
Early Clinical Stage Products 46
Discovery and Pre-Clinical Stage Products 47
Breast Cancer Therapeutics - Products under Development by Companies 48
Breast Cancer Therapeutics - Products under Investigation by Universities/Institutes 82
Companies Involved in Breast Cancer Therapeutics Development 90
Breast Cancer - Therapeutics Assessment 334
Drug Profiles 342
Breast Cancer Therapeutics - Drug Profile Updates 422
Breast Cancer Therapeutics - Discontinued Products 468
Breast Cancer Therapeutics - Dormant Products 476
Breast Cancer - Product Development Milestones 503


Appendix 511


Number of Products Under Development for Breast Cancer, H2 2013 23
Products under Development for Breast Cancer - Comparative Analysis, H2 2013 24
Number of Products under Development by Companies, H2 2013 26
Number of Products under Development by Companies, H2 2013 (Contd..1) 27
Number of Products under Development by Companies, H2 2013 (Contd..2) 28
Number of Products under Development by Companies, H2 2013 (Contd..3) 29
Number of Products under Development by Companies, H2 2013 (Contd..4) 30
Number of Products under Development by Companies, H2 2013 (Contd..5) 31
Number of Products under Development by Companies, H2 2013 (Contd..6) 32
Number of Products under Development by Companies, H2 2013 (Contd..7) 33
Number of Products under Development by Companies, H2 2013 (Contd..8) 34
Number of Products under Development by Companies, H2 2013 (Contd..9) 35
Number of Products under Development by Companies, H2 2013 (Contd..10) 36
Number of Products under Development by Companies, H2 2013 (Contd..11) 37
Number of Products under Development by Companies, H2 2013 (Contd..12) 38
Number of Products under Development by Companies, H2 2013 (Contd..13) 39
Number of Products under Development by Companies, H2 2013 (Contd..14) 40
Number of Products under Development by Companies, H2 2013 (Contd..15) 41
Number of Products under Development by Companies, H2 2013 (Contd..16) 42
Number of Products under Development by Companies, H2 2013 (Contd..17) 43
Number of Products under Development by Companies, H2 2013 (Contd..18) 44
Number of Products under Development by Companies, H2 2013 (Contd..19) 45
Number of Products under Investigation by Universities/Institutes, H2 2013 47
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 48
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..2) 49
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..3) 50
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..4) 51
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..5) 52
Comparative Analysis by Late Stage Development, H2 2013 53
Comparative Analysis by Mid Clinical Stage Development, H2 2013 54
Comparative Analysis by Early Clinical Stage Development, H2 2013 55
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 56
Products under Development by Companies, H2 2013 57
Products under Development by Companies, H2 2013 (Contd..1) 58
Products under Development by Companies, H2 2013 (Contd..2) 59
Products under Development by Companies, H2 2013 (Contd..3) 60
Products under Development by Companies, H2 2013 (Contd..4) 61
Products under Development by Companies, H2 2013 (Contd..5) 62
Products under Development by Companies, H2 2013 (Contd..6) 63
Products under Development by Companies, H2 2013 (Contd..7) 64
Products under Development by Companies, H2 2013 (Contd..8) 65
Products under Development by Companies, H2 2013 (Contd..9) 66
Products under Development by Companies, H2 2013 (Contd..10) 67
Products under Development by Companies, H2 2013 (Contd..11) 68
Products under Development by Companies, H2 2013 (Contd..12) 69
Products under Development by Companies, H2 2013 (Contd..13) 70
Products under Development by Companies, H2 2013 (Contd..14) 71
Products under Development by Companies, H2 2013 (Contd..15) 72
Products under Development by Companies, H2 2013 (Contd..16) 73
Products under Development by Companies, H2 2013 (Contd..17) 74
Products under Development by Companies, H2 2013 (Contd..18) 75
Products under Development by Companies, H2 2013 (Contd..19) 76
Products under Development by Companies, H2 2013 (Contd..20) 77
Products under Development by Companies, H2 2013 (Contd..21) 78
Products under Development by Companies, H2 2013 (Contd..22) 79
Products under Development by Companies, H2 2013 (Contd..23) 80
Products under Development by Companies, H2 2013 (Contd..24) 81
Products under Development by Companies, H2 2013 (Contd..25) 82
Products under Development by Companies, H2 2013 (Contd..26) 83
Products under Development by Companies, H2 2013 (Contd..27) 84
Products under Development by Companies, H2 2013 (Contd..28) 85
Products under Development by Companies, H2 2013 (Contd..29) 86
Products under Development by Companies, H2 2013 (Contd..30) 87
Products under Development by Companies, H2 2013 (Contd..31) 88
Products under Development by Companies, H2 2013 (Contd..32) 89
Products under Development by Companies, H2 2013 (Contd..33) 90
Products under Investigation by Universities/Institutes, H2 2013 91
Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 92
Products under Investigation by Universities/Institutes, H2 2013 (Contd..2) 93
Products under Investigation by Universities/Institutes, H2 2013 (Contd..3) 94
Products under Investigation by Universities/Institutes, H2 2013 (Contd..4) 95
Products under Investigation by Universities/Institutes, H2 2013 (Contd..5) 96
Products under Investigation by Universities/Institutes, H2 2013 (Contd..6) 97
Products under Investigation by Universities/Institutes, H2 2013 (Contd..7) 98
Bristol-Myers Squibb Company, H2 2013 99
Johnson & Johnson, H2 2013 100
Boehringer Ingelheim GmbH, H2 2013 101
F. Hoffmann-La Roche Ltd., H2 2013 102
Kyowa Hakko Kirin Co., Ltd., H2 2013 103
Celsion Corporation, H2 2013 104
Biogen Idec Inc., H2 2013 105
Amgen Inc., H2 2013 106
Sanofi-Aventis, H2 2013 107
Adherex Technologies Inc., H2 2013 108
AstraZeneca PLC, H2 2013 109
Eli Lilly and Company, H2 2013 110
Viralytics Ltd., H2 2013 111
GlaxoSmithKline plc, H2 2013 112
Bioniche Life Sciences, Inc., H2 2013 113
Tekmira Pharmaceuticals Corp., H2 2013 114
Genentech, Inc., H2 2013 115
Nektar Therapeutics, H2 2013 116
Inovio Biomedical Corporation, H2 2013 117
Biotec Pharmacon ASA ,H2 2013 118
Watson Pharmaceuticals, Inc., H2 2013 119
Bavarian Nordic A/S, H2 2013 120
MedImmune LLC, H2 2013 121
Biotest AG, H2 2013 122
Daiichi Sankyo Company, Ltd, H2 2013 123
Merck & Co., Inc., H2 2013 124
AbGenomics International, Inc., H2 2013 125
FASgen, Inc., H2 2013 126
A&G Pharmaceutical, Inc., H2 2013 127
Oxford BioMedica plc, H2 2013 128
Bioneer Corporation, H2 2013 129
Generex Biotechnology Corporation, H2 2013 130
Plexxikon Inc., H2 2013 131
Ipsen S.A., H2 2013 132
MediGene AG, H2 2013 133
Celltrion, Inc., H2 2013 134
Bio-Path Holdings, Inc., H2 2013 135
BioSante Pharmaceuticals, Inc., H2 2013 136
Histogen, Inc., H2 2013 137
ZIOPHARM Oncology, Inc., H2 2013 138
Millennium Pharmaceuticals, Inc. H2 2013 139
Novartis AG, H2 2013 140
Aphios Corporation, H2 2013 141
Biocon Limited, H2 2013 142
Chong Kun Dang Pharmaceutical, H2 2013 143
Dong-A Pharmaceutical Co., Ltd., H2 2013 144
Eisai Co., Ltd., H2 2013 145
Gedeon Richter Plc., H2 2013 146
GTC Biotherapeutics, Inc., H2 2013 147
GTx, Inc., H2 2013 148
Laboratoires Pierre Fabre SA, H2 2013 149
Nippon Kayaku Co., Ltd., H2 2013 150
Pfizer Inc., H2 2013 151
Sigma-Tau S.p.A., H2 2013 152
Taiho Pharmaceutical Co., Ltd., H2 2013 153
Takara Holdings Inc., H2 2013 154
Teva Pharmaceutical Industries Limited, H2 2013 155
Cell Therapeutics, Inc., H2 2013 156
Enzon Pharmaceuticals, Inc., H2 2013 157
Exelixis, Inc., H2 2013 158
Aduro BioTech, H2 2013 159
Menarini Group, H2 2013 160
Alfacell Corporation, H2 2013 161
CEL-SCI Corporation, H2 2013 162
Celgene Corporation, H2 2013 163
Bayer AG, H2 2013 164
Access Pharmaceuticals, Inc., H2 2013 165
Advaxis, Inc., H2 2013 166
Neogenix Oncology Corporation, H2 2013 167
Alchemia Limited H2 2013 168
EntreMed, Inc., H2 2013 169
GW Pharmaceuticals plc, H2 2013 170
Hana Biosciences, Inc., H2 2013 171
Hollis-Eden Pharmaceuticals, Inc., H2 2013 172
Celldex Therapeutics, Inc., H2 2013 173
Momenta Pharmaceuticals, Inc., H2 2013 174
ValiRx Plc, H2 2013 175
AEterna Zentaris Inc., H2 2013 176
IMMUNOMEDICS, INC, H2 2013 177
Lorus Therapeutics Inc, H2 2013 178
Marshall Edwards, Inc., H2 2013 179
Basilea Pharmaceutica Ltd., H2 2013 180
Bionomics Limited, H2 2013 181


Number of Products under Development for Breast Cancer, H2 2013 23
Products under Development for Breast Cancer - Comparative Analysis, H2 2013 24
Products under Development by Companies, H2 2013 25
Products under Investigation by Universities/Institutes, H2 2013 46
Late Stage Products, H2 2013 53
Mid Clinical Stage Products, H2 2013 54
Early Clinical Stage Products, H2 2013 55
Discovery and Pre-Clinical Stage Products, H2 2013 56
Assessment by Monotherapy Products, H2 2013 343
Assessment by Combination Products, H2 2013 344
Assessment by Route of Administration, H2 2013 345
Assessment by Stage and Route of Administration, H2 2013 346
Assessment by Molecule Type, H2 2013 348
Assessment by Stage and Molecule Type, H2 2013 349